RxDoctor Payments Data

Charles Hattemer, MD

Interventional Cardiology · West Chester, OHNPI 1093714750

Payments from drug & device makers

$1,385in general payments, 2019–2025

Across 39 payments — averaging $35.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Imperative Care, Inc$318
  • Inari Medical, Inc.$246
  • Boston Scientific$224
  • Novartis$97
  • Angiodynamics, Inc.$77
  • Cardiva Medical, Inc.$66
  • plus $356 from 11 others

What the payments were for

  • Food & beverage$1,385100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,385 in reported general payments places this provider in the 20th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$99,173
Medicare patients
506
Services billed
942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$143,075
XareltoRivaroxaban49$68,858
EntrestoSacubitril/Valsartan57$56,795
Repatha SureclickEvolocumab48$36,760
JardianceEmpagliflozin23$18,160
BrilintaTicagrelor17$7,186
Ranolazine ErRanolazine22$4,610
Amiodarone Hcl21$2,390
Metoprolol Succinate180$2,235
Atorvastatin Calcium246$1,513
Candesartan Cilexetil13$1,370
Rosuvastatin Calcium101$1,311
Valsartan31$1,266
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$1,162
Ezetimibe44$1,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$97$56,79557 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in West Chester

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →